Di-n-propylacetic acid en es it fr

Di-n-propylacetic acid Brand names, Di-n-propylacetic acid Analogs

Di-n-propylacetic acid Brand Names Mixture

  • No information avaliable

Di-n-propylacetic acid Chemical_Formula


Di-n-propylacetic acid RX_link


Di-n-propylacetic acid fda sheet

Di-n-propylacetic acid msds (material safety sheet)

Di-n-propylacetic_acid MSDS

Di-n-propylacetic acid Synthesis Reference

Oberreit, Ber.29, 1998 (1896)

Di-n-propylacetic acid Molecular Weight

144.211 g/mol

Di-n-propylacetic acid Melting Point

120 - 130 oC

Di-n-propylacetic acid H2O Solubility

Slightly soluble (1.3 mg/mL)

Di-n-propylacetic acid State


Di-n-propylacetic acid LogP


Di-n-propylacetic acid Dosage Forms

Capsule (250 mg); Syrup (250 mg drug/5mL syrup)

Di-n-propylacetic acid Indication

For use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.

Di-n-propylacetic acid Pharmacology

Valproic Acid is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder. It is also used to treat migraine headaches and schizophrenia. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome. Valproic Acid is believed to affect the function of the neurotransmitter GABA (as a GABA transaminase inhibitor) in the human brain. Valproic Acid dissociates to the valproate ion in the gastrointestinal tract. Valproic acid has also been shown to be an inhibitor of an enzyme called histone deacetylase 1 (HDAC1). HDAC1 is needed for HIV to remain in infected cells. A study published in August 2005 revealed that patients treated with valproic acid in addition to highly active antiretroviral therapy (HAART) showed a 75% reduction in latent HIV infection.

Di-n-propylacetic acid Absorption

Rapid absorption from gastrointestinal tract.

Di-n-propylacetic acid side effects and Toxicity

Oral, mouse: LD50 = 1098 mg/kg; Oral, rat: LD50 = 670 mg/kg. Symptoms of overdose may include coma, extreme drowsiness, and heart problems.

Di-n-propylacetic acid Patient Information

Since valproate products may produce CNS depression, especially when combined with another CNS depressant (eg, alcohol), patients should be advised not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.

Di-n-propylacetic acid Organisms Affected

Humans and other mammals